ATE79372T1 - Markierte antikoerperfragmente. - Google Patents

Markierte antikoerperfragmente.

Info

Publication number
ATE79372T1
ATE79372T1 AT85307064T AT85307064T ATE79372T1 AT E79372 T1 ATE79372 T1 AT E79372T1 AT 85307064 T AT85307064 T AT 85307064T AT 85307064 T AT85307064 T AT 85307064T AT E79372 T1 ATE79372 T1 AT E79372T1
Authority
AT
Austria
Prior art keywords
antibody fragments
coupling agents
maleimide
marked antibody
radionuclide
Prior art date
Application number
AT85307064T
Other languages
English (en)
Inventor
Robert A Nicolotti
Richard T Dean
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Application granted granted Critical
Publication of ATE79372T1 publication Critical patent/ATE79372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT85307064T 1984-10-10 1985-10-02 Markierte antikoerperfragmente. ATE79372T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/659,456 US4659839A (en) 1984-10-10 1984-10-10 Coupling agents for radiolabeled antibody fragments
EP85307064A EP0178125B1 (de) 1984-10-10 1985-10-02 Markierte Antikörperfragmente.

Publications (1)

Publication Number Publication Date
ATE79372T1 true ATE79372T1 (de) 1992-08-15

Family

ID=24645469

Family Applications (2)

Application Number Title Priority Date Filing Date
AT85307064T ATE79372T1 (de) 1984-10-10 1985-10-02 Markierte antikoerperfragmente.
AT91110020T ATE178597T1 (de) 1984-10-10 1985-10-02 Biologisch nützliche konjugate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT91110020T ATE178597T1 (de) 1984-10-10 1985-10-02 Biologisch nützliche konjugate

Country Status (7)

Country Link
US (1) US4659839A (de)
EP (3) EP0455268B1 (de)
JP (1) JPH0647560B2 (de)
AT (2) ATE79372T1 (de)
AU (1) AU598183B2 (de)
CA (1) CA1257601A (de)
DE (2) DE3586479T2 (de)

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5045303A (en) * 1985-05-17 1991-09-03 Neorx Corporation Radiohalogenated small molecules for protein labeling
US5336762A (en) * 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
EP0232693A3 (de) * 1985-12-16 1988-04-06 La Region Wallonne Konjugate des Vinblastins und seiner Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
JP2515357B2 (ja) * 1986-01-16 1996-07-10 ザ・ジェネラル・ホスピタル・コ−ポレ−ション 炎症の診断方法および治療方法
US5271927A (en) * 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US4732974A (en) * 1986-03-05 1988-03-22 Mallinckrodt, Inc. Metal ion labeling of carrier molecules
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US4877868A (en) * 1986-03-12 1989-10-31 Neorx Corporation Radionuclide antibody coupling
US6451225B1 (en) 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5591581A (en) 1986-04-30 1997-01-07 Igen, Inc. Electrochemiluminescent rhenium moieties and methods for their use
US6165729A (en) * 1986-04-30 2000-12-26 Hyperion Catalysis International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US5082930A (en) * 1986-05-29 1992-01-21 Mallinckrodt Medical, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US5482700A (en) * 1987-03-31 1996-01-09 Schering Aktiengesellschaft Substituted polyamino, polycarboxy complexing agent dimers for MRI and X-ray contrast
DE3710730A1 (de) * 1987-03-31 1988-10-20 Schering Ag Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5693309A (en) * 1987-03-31 1997-12-02 Schering Aktiengesellschaft Substituted complexing agents, complexes, and complex salts, processes for their production, and pharmaceuticals containing same
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
US5177192A (en) * 1987-04-02 1993-01-05 Centocor, Incorporated Method for labeling antibodies with a metal ion
US4735792A (en) * 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US4871836A (en) * 1987-10-13 1989-10-03 E. R. Squibb & Sons, Inc. Boronic acid adducts of rhenium and radioactive isotopes of rhenium dioxime complexes
CA1340387C (en) * 1987-10-30 1999-02-09 Carol A. Schlesinger Heterobifunctional coupling agents
ATE259064T1 (de) * 1987-11-04 2004-02-15 Igen Int Inc Lumineszente rhenium-komplexe und verfahren zur herstellung
US5648471A (en) * 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5395946A (en) * 1988-02-09 1995-03-07 Goedemans; Wilhelmus T. Bifunctional chelating agents
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
DE3807904A1 (de) * 1988-03-10 1989-09-21 Behringwerke Ag Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US6702986B1 (en) 1988-04-29 2004-03-09 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5218128A (en) * 1988-06-15 1993-06-08 Centocor, Inc. Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom
US5180816A (en) * 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
JPH03504510A (ja) * 1989-02-10 1991-10-03 セルテック　リミテッド アザマクロサイクルおよびその製法
US5342936A (en) * 1989-02-10 1994-08-30 David Parker Tetra-aza macrocycles and processes for their preparation
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
DE3919915A1 (de) * 1989-06-19 1990-12-20 Boehringer Mannheim Gmbh Aminoalkylmaleimide und davon abgeleitete hapten- und antigenderivate sowie konjugate mit peptiden oder proteinen
US5247077A (en) * 1989-06-23 1993-09-21 Celltech Limited Tri-aza macrocycles and processes for their preparation
DK408289D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Diagnostisk reagens
US5162505A (en) * 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
US5096696A (en) * 1990-02-05 1992-03-17 The Research Foundation Of State University Of New York Binding of radiolabeled albumin fragments to fibrin clots
US5262524A (en) * 1990-03-09 1993-11-16 Hybritech Incorporated Method for the synthesis of trifunctional maleimide-antibody complex
IL97459A0 (en) * 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5185433A (en) * 1990-04-09 1993-02-09 Centocor, Inc. Cross-linking protein compositions having two or more identical binding sites
US5684135A (en) * 1990-04-18 1997-11-04 Celltech Therapeutics Limited Conjugate compounds containing aza-macro-cycles and processes for their preparation
GB2250198B (en) * 1990-04-18 1994-06-22 Celltech Ltd Tetra-aza macrocycles,processes for their preparation and their use in magnetic resonance imaging
US5175256A (en) * 1990-09-28 1992-12-29 Neorx Corporation Protein labeling reagents
JP3093383B2 (ja) * 1990-11-30 2000-10-03 塩野義製薬株式会社 抗体標識のための放射性ヨウ素化合物
CA2070961C (en) * 1991-06-14 2004-12-07 Michael Chorev Thiol-reactive maleimido-based radiolabeling reagents
JPH06509102A (ja) * 1991-07-01 1994-10-13 マリンクロッド・メディカル・インコーポレイテッド 体内造影抗イディオタイプ抗体を用いた組織特異的造影剤
US5346686A (en) * 1992-10-05 1994-09-13 Mallinckrodt Medical, Inc. Labelled interleukin-8 and medical uses thereof
US5605671A (en) * 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
US5413778A (en) * 1992-10-05 1995-05-09 The Regents Of The University Of Michigan Labelled monocyte chemoattractant protein material and medical uses thereof
WO1994009128A1 (en) * 1992-10-22 1994-04-28 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6001364A (en) 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
ES2146649T3 (es) 1993-05-05 2000-08-16 Keith Rose Compuestos de polioximas y su preparacion.
CA2175557A1 (en) * 1993-11-16 1995-05-26 Alfred Pollak Immobilized labelling method
CA2179990A1 (en) * 1994-01-12 1995-07-20 Gary Robert Bower Biological targeting agents
US20030220233A1 (en) * 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
DE19505960A1 (de) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
US20050025740A1 (en) * 1996-01-05 2005-02-03 Keith Rose Polyoxime compounds and their preparation
JP2001521520A (ja) 1997-04-11 2001-11-06 ジー．ディー．サール アンド カンパニー 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト
AU6954498A (en) 1997-04-11 1998-11-11 G.D. Searle & Co. Methods for using antagonistic anti-avb3 integrin antibodies
US6960457B1 (en) 1997-09-04 2005-11-01 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
US7070921B2 (en) 2000-04-28 2006-07-04 Molecular Devices Corporation Molecular modification assays
US7632651B2 (en) * 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
US20050227294A1 (en) * 1997-09-15 2005-10-13 Molecular Devices Corporation Molecular modification assays involving lipids
US7745142B2 (en) * 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US6869604B1 (en) * 1998-03-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant anti-tumor RNAse
EP2085781B2 (de) 2000-10-06 2020-03-11 Life Technologies Corporation Zellen mit spektralen Signaturen und Verfahren zur Herstellung und Verwendung davon
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
WO2002040874A1 (en) * 2000-11-16 2002-05-23 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
JP4342934B2 (ja) * 2001-06-11 2009-10-14 キセノポート インコーポレーティッド Ｐｅｐｔ−２輸送体を介した薬剤の投与
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
US20030031627A1 (en) * 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
US8323903B2 (en) 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
WO2003048295A1 (en) 2001-11-30 2003-06-12 Fluidigm Corporation Microfluidic device and methods of using same
US20030158089A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Administrative agents via the SMVT transporter
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20030228619A1 (en) * 2002-06-10 2003-12-11 Xenoport, Inc. Peptide nucleic acids as tags in encoded libraries
US7029468B2 (en) * 2002-06-25 2006-04-18 Enpath Medical, Inc. Catheter assembly with side wall exit lumen and method therefor
MXPA05000778A (es) 2002-07-18 2005-08-29 Helix Biopharma Corp Uso de ureasa para inhibir el crecimiento de celulas cancerosas.
US20040161424A1 (en) * 2002-10-08 2004-08-19 Xenoport Human organic solute transporters
WO2006102264A1 (en) 2005-03-18 2006-09-28 Fluidigm Corporation Thermal reaction device and method for using the same
WO2004089810A2 (en) 2003-04-03 2004-10-21 Fluidigm Corp. Microfluidic devices and methods of using same
US20050043510A1 (en) * 2003-04-10 2005-02-24 Moeckli Randolph A. Affinity purification system using troponin molecules as affinity ligands
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
CN102532321B (zh) * 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
US7638299B2 (en) * 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
WO2006053380A1 (en) * 2004-11-16 2006-05-26 Sienna Cancer Diagnostics Ltd Methods of detecting an analyte in a sample
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
KR101224781B1 (ko) * 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
NZ555425A (en) 2004-12-22 2010-04-30 Ambrx Inc Compositions of aminoacyl-tRNA synthetase and uses thereof
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
WO2006133088A2 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
CA2618878C (en) * 2005-08-18 2016-06-28 Ambrx, Inc. Compositions of trna and uses thereof
SI1954710T1 (sl) * 2005-11-08 2011-08-31 Ambrx Inc Pospeĺ evala za modifikacijo nenaravnih aminokislin in nenaravnih peptidov aminokislin
EP1951890A4 (de) * 2005-11-16 2009-06-24 Ambrx Inc Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
WO2008030558A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
ES2457527T3 (es) * 2006-09-08 2014-04-28 Ambrx, Inc. ARNt Supresor hibrido en células de vertebrados
PT2064333E (pt) * 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
AU2008222678B2 (en) 2007-03-07 2013-01-17 The General Hospital Corporation Compositions and methods for the prevention and treatment of autoimmune conditions
KR101476472B1 (ko) * 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
KR20100019467A (ko) * 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
EP2192922A4 (de) 2007-09-17 2010-09-29 Univ California Auf prostatazellen in situ abzielende internalisierende humane monoklonale antikörper
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CN102014959B (zh) 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
MX2011000859A (es) 2008-07-23 2011-02-24 Ambrx Inc Polipeptidos g-csf bovinos modificados y sus usos.
NO2337846T3 (de) 2008-09-26 2018-06-16
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
ES2626327T3 (es) 2009-02-06 2017-07-24 The Regents Of The University Of California Agentes enlazantes de calcio que inducen crecimiento del cabello y/o crecimiento de las uñas
ES2845212T3 (es) 2009-04-13 2021-07-26 Inst Nat Sante Rech Med Partículas de HPV y usos de las mismas
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US20120055055A1 (en) 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
WO2012036746A1 (en) 2010-09-15 2012-03-22 Randall J Mrsny Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
RU2635537C2 (ru) 2010-09-29 2017-11-13 Ютиай Лимитед Партнершип Способ лечения аутоиммунного заболевания с использованием биосовместимых биоабсорбируемых наносфер
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN105388287A (zh) 2011-03-11 2016-03-09 内布拉斯加大学董事委员会 冠状动脉疾病的生物标志物
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
CN103717595A (zh) 2011-05-27 2014-04-09 Ambrx公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
EP2714685B1 (de) 2011-05-27 2016-10-19 Ambrx, Inc. Zusammensetzungen, enthaltend mit nichtnatürlichen aminosäuren verknüpfte dolastatin-derivate, sowie verfahren dafür und anwendungen davon
US20130116408A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
CA2866126A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
MX363116B (es) 2012-06-07 2019-03-11 Ambrx Inc Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
AU2013274078A1 (en) 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
EP4406612A3 (de) 2012-06-19 2024-10-16 Ambrx, Inc. Anti-cd70-antikörper-arzneimittelkonjugate
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
HK1216903A1 (zh) 2013-04-08 2016-12-09 赫利克斯生物药品公司 抗体-尿素酶偶联物在诊断和治疗中的应用
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EP4059521A1 (de) 2013-09-18 2022-09-21 Aura Biosciences, Inc. Virusähnliche partikelkonjugate zur diagnose und behandlung von tumoren
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
JP2017500285A (ja) 2013-11-04 2017-01-05 ユーティーアイ リミテッド パートナーシップ 持続的免疫療法のための方法および組成物
SG11201610183XA (en) 2014-05-07 2017-01-27 Applied Molecular Transp Llc Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2016054591A1 (en) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
SG10201913957PA (en) 2015-05-06 2020-03-30 Uti Lp Nanoparticle compositions for sustained therapy
CN108473950A (zh) 2015-10-30 2018-08-31 美国政府卫生与公众服务部 靶向癌症治疗
CA3002573A1 (en) 2015-11-03 2017-05-11 Ambrx, Inc. Anti-cd3 antibodies and their uses
ES2975747T3 (es) 2015-11-30 2024-07-12 Univ California Administración de carga útil específica de tumor y activación inmunitaria utilizando un anticuerpo humano que se dirige a un antígeno de superficie celular de tumor altamente específico
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
AU2017250507B2 (en) 2016-04-12 2021-05-27 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
EP3515459A4 (de) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center Kardiosphärenzellen und deren extrazelluläre vesikel zur verzögerung oder umkehr des alterungsprozesses und altersbedingten erkrankungen
WO2018089829A1 (en) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
WO2018089807A2 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
EP3548097A4 (de) 2016-12-02 2020-07-01 Avelas Biosciences, Inc. Nervenmarkierungszusammensetzungen und verwendungen davon
US20180163270A1 (en) 2016-12-12 2018-06-14 Cepheid Integrated immuno-pcr and nucleic acid analysis in an automated reaction cartridge
CA3049212A1 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
EP3610243A4 (de) 2017-04-07 2020-12-16 Avelas Biosciences, Inc. Ratiometrische fluoreszenzbildgebungsverfahren
CA3059882A1 (en) 2017-04-12 2018-10-18 Aura Biosciences, Inc. Targeted combination therapy
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
ES2998689T3 (en) 2017-08-02 2025-02-21 Univ California Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic delivery
JP7436372B2 (ja) 2017-11-29 2024-02-21 ユーティアイ・リミテッド・パートナーシップ 自己免疫性疾患を治療する方法
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2019152549A1 (en) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas
KR20250174998A (ko) 2018-03-08 2025-12-15 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
CA3093386A1 (en) 2018-03-08 2019-09-12 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
WO2019191728A1 (en) 2018-03-29 2019-10-03 Ambrx, Inc. Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
KR20210063351A (ko) 2018-08-28 2021-06-01 암브룩스, 인코포레이티드 항-cd3 항체 폴레이트 생체접합체 및 이들의 용도
MX2021002575A (es) 2018-09-11 2021-06-08 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化
WO2021072289A1 (en) 2019-10-10 2021-04-15 Alume Biosciences, Inc. Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
AU2021320333A1 (en) 2020-08-07 2023-03-30 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
US20240207421A1 (en) 2020-12-04 2024-06-27 Alume Biosciences, Inc. Nerve targeting peptides and methods of use
KR20230137930A (ko) 2021-01-14 2023-10-05 알룸 바이오사이언시스 인코포레이티드 수술 절차에서 요관을 가시화하기 위한 방법 및 조성물
MX2023011480A (es) 2021-04-03 2023-12-06 Ambrx Inc Conjugados anticuerpo anti-her2-fármaco y usos de estos.
CN120344270A (zh) 2022-10-07 2025-07-18 Ambrx 公司 药物接头及其抗体缀合物
IL322121A (en) 2023-01-16 2025-09-01 Ambrx Inc Anti-CD70 antibody-drug conjugates
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2025041055A1 (en) 2023-08-22 2025-02-27 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
US4308249A (en) * 1979-12-13 1981-12-29 G. D. Searle & Co. Radiopharmaceutical complexes of N-(tri-substituted alkyl)-iminodiacetic acids
NO169947C (no) * 1981-10-27 1992-08-26 Hybritech Inc Fremgangsmaate for fremstilling av et monoklonalt antistoff til et tumorassosiert antigen
JPS59215321A (ja) * 1983-05-23 1984-12-05 Sumitomo Chem Co Ltd 二官能性配位子化合物を結合した反応性高分子
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments

Also Published As

Publication number Publication date
AU4845185A (en) 1986-04-17
DE3586479T2 (de) 1993-03-18
AU598183B2 (en) 1990-06-21
EP0178125A3 (en) 1987-07-01
EP0911323A1 (de) 1999-04-28
EP0178125B1 (de) 1992-08-12
US4659839A (en) 1987-04-21
DE3588210T2 (de) 1999-11-11
DE3586479D1 (de) 1992-09-17
ATE178597T1 (de) 1999-04-15
DE3588210D1 (de) 1999-05-12
JPS6193131A (ja) 1986-05-12
JPH0647560B2 (ja) 1994-06-22
EP0455268B1 (de) 1999-04-07
EP0178125A2 (de) 1986-04-16
CA1257601A (en) 1989-07-18
EP0455268A1 (de) 1991-11-06

Similar Documents

Publication Publication Date Title
DE3586479D1 (de) Markierte antikoerperfragmente.
DE3766157D1 (de) Kupplungsmittel zum radiomarkieren von proteinen.
ATE120457T1 (de) Macrocyclische bifunktionelle chelatbildner, komplexe davon und ihre konjugierten antikörper.
DE3162157D1 (en) 99m tc labeled diagnostic compositions and method for making the same
ATE63919T1 (de) Platinkoordinationsverbindungen.
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
DE3578625D1 (de) Radioaktiv markierte antikoerperstuecke.
DK39985A (da) Fremgangsmaade til radioaktiv maerkning af diagnostiske og terapeutiske midler indeholdende et cheleringsmiddel
DK165488D0 (da) Metalchelaterende forbindelser og chelatforbindelser
NO903762D0 (no) Fremgangsmaate for aa opprette diffusjonsbinding mellom korrosjonsbestandige materialer.
FR2567596B1 (fr) Agrafe pour l'assemblage de pieces, telles que des panneaux
ATE296312T1 (de) Metalkomplexbildner
DE69433114D1 (de) Metallion-ligand koordinationskomplexe, antikorper dagegen und tests die solche antikorper verwenden
DK541389A (da) Chelateringsmidler med ortho-bindende funktionalitet og komplekser omfattende disse
DE58900348D1 (de) Rohrschelle als buegelschelle.
DK0772459T3 (da) Technetium-99m mærkede billeddannende midler.
FI791661A7 (fi) Menetelmä erillisten osien, kuten putkijohdon ja levyn, putken tai sen tapaisen kappaleen liittämiseksi yhteen.
FI830851A7 (fi) Menetelmiä muokattavien ja pallografiittivalurautojen valmistamiseksi.
YU46858B (sh) Postupak za dobijanje imunoglobulinskih konjugata
GB8401714D0 (en) Ferritic ductile iron parts
FR2505419B1 (fr) Agrafe metallique en u
KR850008896U (ko) 철관 이음쇠
ES1007727U (es) Dispositivo para la union de elementos de construccion de hormigon o similares que contactan de manera plana.
ES1024566U (es) Fondo-base para carteras y similares.
NO882518L (no) Fremgangsmaater ved forbedret binding til antistoff, antistoff-fragmenter, hormoner og andre bindingsmidler, og konjugater derav.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee